Under the terms of the agreement, and subject to achievement of certain milestones, Sentynl will acquire full rights to the molecule for HGPS upon closing. Progerinin will become the company’s second therapy intended for the treatment of HGPS. The programme is currently finalising a Phase 2A clinical trial, with data expected before the end of 1H 2026.
Progerinin is an investigational, orally active small-molecule drug candidate being developed as a potential treatment for HGPS, a rare genetic disorder characterised by accelerated ageing in children. The disease is caused by the accumulation of progerin, an abnormal form of the lamin A protein produced by mutations in the LMNA gene, which disrupts nuclear structure and leads to premature cellular ageing. The molecule is designed to inhibit the interaction and harmful effects of progerin within cells, thereby improving nuclear integrity and reducing cellular damage. It is not currently approved by the US Food and Drug Administration or any other health authority.
Early research and clinical trials are aimed at determining whether Progerinin can slow disease progression and improve survival in HGPS patients, potentially offering another therapeutic option.
Also read: Zydus Life may acquire US-firm Ardelyx, may raise funds via QIP to part-fund deal: Exclusive
On the NSE, Zydus Lifesciences Limited shares closed at ₹886.90, down ₹19.00 or 2.10%, after trading at ₹885.45, down ₹20.45 or 2.26%.
